Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Over the past fifty years, intellectual property has not played a major role in the spread of assisted reproductive technology, but with in vitro gametogenesis — a technique likely to dominate the future of reproduction — it might.
Recent patents relating to employing metabolomic data to diagnose disease states and determine the likelihood that a patient will respond to certain treatments.
Legal barriers are preventing generic drug makers from being able to utilize the Patent Trial and Appeal Board for its intended purpose — to serve as a faster and less cumbersome alternative to district court litigation.
The COVID-19 pandemic dispelled some myths underlying intellectual property policy and revealed how stakeholders can develop policies to accelerate development and ensure access using existing tools and experimenting with open science.
Manufacturers of brand-name nebulizer solutions have employed a variety of strategies to preserve market dominance over their products but have been less successful than manufacturers of brand-name inhalers in preventing generic competition.
Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.
